vimarsana.com
Home
Live Updates
New Novartis data show early addition of twice-yearly* : vimarsana.com
New Novartis data show early addition of twice-yearly*
V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal...
Related Keywords
United States ,
South Korea ,
China ,
Switzerland ,
Netherlands ,
Amsterdam ,
Noord Holland ,
Japan ,
America ,
Swiss ,
Han ,
American ,
Jonathan Graham ,
Richard Jarvis ,
Isabella Zinck ,
Satoshi Sugimoto ,
Nicole Zinsli Somm ,
Coll Cardiol ,
Parag Mahanti ,
Michael Meo ,
Imke Kappes ,
Michael Koren ,
Marlena Abdinoor ,
Sloan Simpson ,
American Heart Association ,
Novartis Pharmaceuticals Corp ,
American College Of Cardiology Congress ,
Instagram ,
Alnylam Pharmaceuticals ,
European Society Of Cardiology Congress ,
World Health Organization ,
European Union ,
Jacksonville Center ,
Journal Of The American College Cardiology ,
Linkedin ,
Exchange Commission ,
European Medicines Agency ,
Facebook ,
World Heart Federation ,
American College Of Cardiology Heart Association ,
Clinical Research ,
Public Health ,
National Medical Products Administration ,
Novartis ,
Health Promotion Series ,
Annual Scientific Session ,
American College ,
Medical Director ,
Atherosclerotic Cardiovascular Disease ,
Cardiology Congress ,
European Society ,
Medical Products ,
Pharmaceuticals Corp ,
American Heart ,
American Heart Association Task Force ,
Clinical Practice ,
World Heart ,
Published May ,
Swiss Stock Exchange Novn ,
Novartis Pharma Ag ,
Media Release ,
Reimagine Medicine ,
Medical Innovations ,
vimarsana.com © 2020. All Rights Reserved.